Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248331 | 0.88 | NPC1 (0.60) | NPC1RAB9AMAPTKDM4ECHRM5 | |
| SCHEMBL28983188 | 0.81 | CHRM5 (0.71) | MAPTCHRM5SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL28983145 | 0.78 | CHRM5 (0.73) | MAPTCHRM5SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4900109 | 0.77 | TRPV1 (0.56) | NPC1RAB9AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL5783405 | 0.76 | TRPV1 (0.76) | NPC1RAB9AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL12779258 | 0.73 | MCHR1 (0.52) | MCHR1MAPTDEGS1ALDH1A1L3MBTL1 | |
| SCHEMBL12514122 | 0.73 | SMN1; SMN2 (0.45) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5798843 | 0.73 | RAB9A (0.65) | NPC1RAB9AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL4988089 | 0.72 | TRPV1 (0.56) | NPC1RAB9AMAPTSMN1; SMN2DEGS1 | |
| SCHEMBL28983104 | 0.72 | CHRM5 (0.73) | MAPTCHRM5SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | claimed |
| EP-1606289-B1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | claimed |
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-1606289-B1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7531558-B2 | e.g. 6-(4-Fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; vanilloid (capsaicin) receptor modulator; analgesic; chronic, neuropathic, postoperative, postrheumatoid arthritic, osteoarthritic, back, cancer, dental pain, algesia, neuralgia, migraine, neuropathies, ischaemia | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20060148855-A1 | Carboxamide derivatives | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148855-A1 | Carboxamide derivatives | CNR2, CNR1, SUCNR1 | MCHR1 1960/4885NPC1 2461/4885RAB9A 2395/4885 |
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | TRPV1, CNR1, OPRM1 | MCHR1 504/4885NPC1 623/4885RAB9A 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.